- Home
- CJMB vs EVAX Comparison
CJMB vs EVAX Comparison
Compare CJMB & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJMB
- EVAX
- Stock Information
- Founded
- CJMB 2007
- EVAX 2008
- Country
- CJMB United States
- EVAX Denmark
- Employees
- CJMB N/A
- EVAX N/A
- Industry
- CJMB
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CJMB
- EVAX Health Care
- Exchange
- CJMB NYSE
- EVAX Nasdaq
- Market Cap
- CJMB 18.8M
- EVAX 16.3M
- IPO Year
- CJMB 2025
- EVAX 2021
- Fundamental
- Price
- CJMB $5.54
- EVAX $2.53
- Analyst Decision
- CJMB
- EVAX Strong Buy
- Analyst Count
- CJMB 0
- EVAX 3
- Target Price
- CJMB N/A
- EVAX $33.33
- AVG Volume (30 Days)
- CJMB 891.7K
- EVAX 6.8M
- Earning Date
- CJMB 01-01-0001
- EVAX 03-26-2025
- Dividend Yield
- CJMB N/A
- EVAX N/A
- EPS Growth
- CJMB N/A
- EVAX N/A
- EPS
- CJMB N/A
- EVAX N/A
- Revenue
- CJMB $6,884,783.00
- EVAX $3,295,000.00
- Revenue This Year
- CJMB N/A
- EVAX $9,039.73
- Revenue Next Year
- CJMB N/A
- EVAX $1.47
- P/E Ratio
- CJMB N/A
- EVAX N/A
- Revenue Growth
- CJMB N/A
- EVAX N/A
- 52 Week Low
- CJMB $3.38
- EVAX $2.22
- 52 Week High
- CJMB $7.76
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- CJMB N/A
- EVAX 40.91
- Support Level
- CJMB N/A
- EVAX $2.43
- Resistance Level
- CJMB N/A
- EVAX $2.80
- Average True Range (ATR)
- CJMB 0.00
- EVAX 0.31
- MACD
- CJMB 0.00
- EVAX 0.07
- Stochastic Oscillator
- CJMB 0.00
- EVAX 16.94
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.